BNT-325 by BioNTech for Malignant Mesothelioma: Likelihood of Approval

BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma.

Higher plant-based protein intake linked to lower heart disease risk

Eating a diet with a higher ratio of plant-based protein to animal-based protein may reduce the risk of cardiovascular disease (CVD) and coronary heart disease

December 2, 2024

House hearing keeps pressure on PBM practices while Congress considers reforms

The House Oversight Committee kept pressure on drug middlemen at a hearing today that focused on a new committee report that criticizes industry practices. Pharmacy

July 23, 2024

Inovalon Acquires VigiLanz, Expanding Reach in Clinical Surveillance and Patient Safety

What You Should Know: – Inovalon, a provider of cloud-based healthcare data analytics solutions, announced today the acquisition of VigiLanz, a prominent provider of SaaS-based

February 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.